Diabetic Lancets Companies Market Position Advancements, Value Creation, Cross-border Expansion, Patent Expansions, Financial Performance Evaluation, Risk Mitigation, Licensing and Monetization, Efficiency Metrics

Diabetic Lancets Key Players and their Developments

The global diabetic lancets market was estimated at US$ 0.93 billion in 2023 and is projected to grow to US$ 2.61 billion by 2034, rising at a compound annual growth rate (CAGR) of 9.84% from 2024 to 2034.

Top Companies in the Diabetic Lancets:

• Becton
• Dickinson and Company
• Terumo Corporation
• Abbott Laboratories
• B. Braun SE
• Greiner-Bio One International GmbH
• Allison Medical Inc.
• Nipro Corporation
• Medtronic
• Astellas Pharma

Latest Announcements by Leaders

• In August 2024, Jared Watkin, executive vice president of Abbott’s diabetes care business, announced the partnership between Medtronic and Abbott, the two global leaders in glucose sensing technology and insulin delivery. The partnership aims to expand Simplera CGM of Medtronic.
• In January 2024, Tom Polen, CEO of Becton Dickinson, explained the importance of new technology for medical device manufacturers to save hospital expenditure. He also reported the company’s investment in automated equipment for laboratories and pharmacies.

Recent Developments in the Diabetic Lancets Market

• In March 2023, Astellas Pharma announced an agreement with Roche Diabetes Care Japan Co. Ltd. to develop and commercialize Roche Diabetes Care’s Accu-Chek Guide Me blood glucose monitoring system.
• In September 2023, Medtronic Plc announced the CE mark for its new Simplera Continuous Glucose Monitor, which is equipped with a disposable all-in-one design.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com